NEW
YORK, Feb. 3, 2025 /PRNewswire/ -- Baird Medical
Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the
"Company"), a leader in microwave ablation (MWA) technology, made a
significant impact at the 2025 North American Society for
Interventional Thyroidology (NASIT) conference. Building on the
success of its NASIT 2024 participation, Baird Medical returned to
this premier event to engage with industry leaders and showcase the
clinical advantages of its cutting-edge MWA technology for thyroid
treatment.
Baird Medical's exhibit drew strong interest, sparking in-depth
discussions with clinicians about the future of minimally invasive
thyroid therapies. The Company provided expert insights into MWA's
efficacy and safety in treating thyroid nodules, addressing key
concerns from physicians. Hands-on demonstrations allowed attendees
to experience the technology's precision and efficiency firsthand,
further reinforcing Baird Medical's leadership in the field.
A highlight of the conference was a keynote presentation by Dr.
Emad Kandil, Professor and Ellis
Hanna Chair in Surgery at Tulane
University School of Medicine. Dr. Kandil shared compelling
case studies and clinical data demonstrating MWA's role as a safe,
effective, and minimally invasive alternative to traditional
thyroid surgery. He emphasized key benefits, including reduced
procedure times, fewer complications, and improved patient
outcomes. The session attracted a large audience and ignited
dynamic discussions, highlighting the industry's strong interest in
MWA technology and providing robust support for Baird Medical's
vision of minimally invasive treatment.
Baird Medical's presence at NASIT 2025 reaffirmed its commitment
to advancing patient care through innovation. By deepening
collaborations with medical professionals, the Company continues to
drive progress in minimally invasive thyroid treatments. Looking
ahead, Baird Medical aims to leverage further research
breakthroughs and strategic partnerships to enhance treatment
options for patients and propel advancements in minimally invasive
therapies.
About Baird Medical
Baird Medical is a leading provider of minimally invasive microwave
ablation (MWA) technology, offering advanced treatment solutions
for conditions such as thyroid nodules, breast disease, uterine
fibroids, and liver cancer. A publicly traded company on NASDAQ,
Baird Medical is dedicated to enhancing patient care through
precision, efficiency, and safety in its innovative medical
devices. For more information, please visit
https://bairdmed.com/
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the United States Private Securities Litigation
Reform Act of 1995. Forward-looking statements are statements that
are not historical facts and generally relate to future events or
Baird Medical's future financial or operational performance. In
some cases, you can identify forward-looking statements by
terminology such as "may," "might," "will," "should," "expect,"
"intend," "plan," "anticipate," "believe," "estimate," "predict,"
"potential," "continue," or the negative of these terms or other
similar expressions.
These forward-looking statements are subject to risks,
uncertainties, and assumptions that could cause actual results or
outcomes to differ materially from those expressed or implied.
These statements are based on estimates and assumptions that, while
considered reasonable by Baird Medical and its management, are
inherently uncertain. Risks and uncertainties may emerge over time,
and it is not possible to anticipate all potential factors that
could affect Baird Medical's business and financial
performance.
Factors that could cause actual results to differ materially
include, but are not limited to: (1) the risk that Baird Medical
may not achieve its expansion goals in the United States, China, or other markets; (2) changes in
economic, regulatory, or market conditions that impact Baird
Medical's operations; (3) the ability to realize anticipated
benefits from ongoing business initiatives or strategic
transactions; (4) regulatory developments and compliance with
applicable laws; (5) risks related to the development,
commercialization, and market acceptance of Baird Medical's
products; and (6) other risks and uncertainties detailed in Baird
Medical's filings with the SEC.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date they
are made. Baird Medical undertakes no obligation to update or
revise forward-looking statements, whether as a result of new
information, future events, or otherwise, except as required by
law. All forward-looking statements in this press release are
qualified in their entirety by this cautionary statement.
Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/baird-medical-showcases-groundbreaking-mwa-innovations-at-nasit-2025-302366242.html
SOURCE BDMD
